crt-0066101 and sphingosine-1-phosphate

crt-0066101 has been researched along with sphingosine-1-phosphate* in 1 studies

Other Studies

1 other study(ies) available for crt-0066101 and sphingosine-1-phosphate

ArticleYear
Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro.
    Experimental cell research, 2013, Aug-01, Volume: 319, Issue:13

    Glioblastoma multiforme (GBM) is the most common malignant brain tumor, which, despite combined modality treatment, reoccurs and is invariably fatal for affected patients. Recently, a member of the serine/threonine protein kinase D (PRKD) family, PRKD2, was shown to be a potent mediator of glioblastoma growth. Here we studied the role of PRKD2 in U87MG glioblastoma cell migration and invasion in response to sphingosine-1-phosphate (S1P), an activator of PRKD2 and a GBM mitogen. Time-lapse microscopy demonstrated that random cell migration was significantly diminished in response to PRKD2 silencing. The pharmacological PRKD family inhibitor CRT0066101 decreased chemotactic migration and invasion across uncoated or matrigel-coated Transwell inserts. Silencing of PRKD2 attenuated migration and invasion of U87MG cells even more effectively. In terms of downstream signaling, CRT0066101 prevented PRKD2 autophosphorylation and inhibited p44/42 MAPK and to a smaller extent p54/46 JNK and p38 MAPK activation. PRKD2 silencing impaired activation of p44/42 MAPK and p54/46 JNK, downregulated nuclear c-Jun protein levels and decreased c-Jun(S73) phosphorylation without affecting the NFκB pathway. Finally, qPCR array analyses revealed that silencing of PRKD2 downregulates mRNA levels of integrin alpha-2 and -4 (ITGA2 and -4), plasminogen activator urokinase (PLAU), plasminogen activator urokinase receptor (PLAUR), and matrix metallopeptidase 1 (MMP1). Findings of the present study identify PRKD2 as a potential target to interfere with glioblastoma cell migration and invasion, two major determinants contributing to recurrence of glioblastoma after multimodality treatment.

    Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Evaluation, Preclinical; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lysophospholipids; MAP Kinase Signaling System; Neoplasm Invasiveness; Protein Kinase D2; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; Sphingosine

2013